Recurrence of urinary tract infection depends on the bacterial strain, found new study published in journal PLOS Pathogens by Thomas Hannan and Scott Hultgren of Washington University School of Medicine, and colleagues. As noted by the authors, the study suggests that the development of a broad-spectrum vaccine should take into account the genetically diverse pathogens that women encounter in the community.
Many patients suffer from highly recurrent urinary tract infections caused by Escherichia coli, which are genetically diverse bacteria. A better understanding of host-pathogen interactions is urgently needed for effective drug and vaccine development in the era of increasing antibiotic resistance. To address this gap in knowledge, Hannan and Hultgren used a mouse model to compare the effects of two E. coli strains that cause urinary tract infections.
They found that one strain, UTI89, could infect the bladder indefinitely, whereas strain CFT073 was always cleared within eight weeks. After mice had a CFT073 infection and antibiotic treatment, they were protected from a CFT073 challenge infection, but were susceptible to a UTI89 challenge infection. By contrast, mice with a UTI89 infection and antibiotics were susceptible to recurrent urinary tract infections when challenged with either strain.
The findings show that infection with one E. coli strain could trigger a protective immune response, while another strain sidestepped this response. According to the authors, the results shed new light on immune responses to urinary tract infections and may be important for drug and vaccine development.
The authors conclude, "This study shows that some bacteria hide from the immune system to cause urinary tract infections again and again."